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INTRODUCTION 
A sustained-release dosage form is defined as 
“any drug or dosage form modification thatprolongs the 
therapeutic activity of the drug” 1. Development of oral 
sustained release (SR) tablets of highly water soluble 
drugs or bioactives has always been a challenge and 
therefore, opportunity for formulation scientist. Most of 
these drugs if not formulated properly, may be released 
at a faster rate resulting in exceeding the maximum 
therapeutic levels and hence will lead to toxic side 
effects. Sustained delivery of such drugs ensures 
improved drug delivery and patient compliance, greater 
safety and efficacy, desired release kinetics and helps in 
maintaining the plasma drug concentration within the 
therapeutic window for extended period of time 
2, 3. 
Lipids like glycerides are a family of excipients which 
have generated considerable interest in the preparation 
of oral dosage forms. Some glycerides such as 
Compritol ATO 888 (glyceryl behenate), Precirol ATO 
5 (glyceryl palmitostearate) can be used for the 
preparation of sustained release dosageforms 
5.
 The 
esterification of glycerol by long chain fatty acid gives 
them a pronounced hydrophobic character with a low 
HLB value of 2 
6.
 Several techniques including melt 
granulation 
7
, melt pelletization 
8
, hot melt extrusion 
9
 
and hot melt coating 
10
 have been used to obtain 
sustained release dosage forms from glycerides-based 
formulations. 
Melt granulation (MG) is a solvent-free 
process which involves the use of a substance that melts 
at a relatively low temperature. This substance can be 
added in the molten form over the substrate or in the 
solid form, which is then heated above its melting point. 
The substance acts as a liquid binding agent, and the 
technique does not require the use of organic solvents. 
Moreover, in melt granulation drying is not necessary 
and thus, the process is less consuming in terms of time 
and energy compared to other methods 
4
. Sustained 
release matrix tablets have been produced with 
Compritol ATO 888 & Precirolby various methods 
including MG
11
, Co-processing and direct compression 
(DC)
12.
 
Nateglinide, N-(trans-4-isopropylcyclohexylcarbonyl)-
D-phenylalanine] is a phenylalanine derivative 
lackingeither a sulfonylurea or benzamido moiety, 
which can restore the physical insulin secretion pattern 
lost in type 2 diabetes mellitus patients with 
postprandial hyperglycemia. Pharmacologically, 
nateglinide reportedly acts on pancreatic cells via the 
closure of the adenosine triphosphate–sensitive 
potassium channels by binding to sulphonylurea 
receptor subunits causingcell depolarization, calcium 
influx, and insulin release.The drug has a rapidonset 
and short duration of insulinotropic action (t½ is _1.5 
hours and Tmax is_0.5–1.0 hour after dosing).13,14 
 
 
 
 
 
 
 
Figure 1: Nateglinide structure 
 
 
ABSTRACT 
The objective of this work was to prepare and evaluate oral sustained release matrix tablet of Nateglinide and to study the effect 
of proportion of wax and addition of release liner on in-vitro release of drug.The prepared tablets were evaluated for pre and 
post compression parameters. Stability study of the promising formulation was also performed. The matrix tablets were 
prepared by Direct compression, Co-processed & melt granulation, method using wax in concentration 25%, 35% & 45% and 
evaluated for on in-vitro drug release using Compritol & Precirol. No interactions were found between drug and excipients. 
Formulation containing 25% Precirol F13 shows releases up to 12 hours. Tablets with release characteristics offers critical 
advantages such as site specificity with improved absorption and efficacy etc. 
Keywords: Nateglinide, Sustained release, Compritol 888, Precirol ATO 5, Melt Granulation, Direct compression, Co-
processing   
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MATERIALS AND METHODS 
Materials 
Nateglinide was a gift from Pure chem, 
Bharuch, India while Compritol ATO 888 and 
Precirolwere obtained free of charge from Gattefosse 
SAS India. Di-Calcium phosphate, magnesium stearate, 
Aerosil 200, concentrated hydrochloric acid, sodium 
hydroxide and potassium dihydrogen phosphate were 
purchased from SD Fine chemicals, Mumbai, India. 
Distilled water (D.W.)was prepared freshly whenever 
required. Other chemicals and reagents used were of 
analytical grade. 
Methods  
Preparation of Nateglinide matrix tablets 
Preparation of wax matrix tablets was done by three 
methods: Melt granulation, Co-processing and Direct 
compression as follows. 
Identification of drug: 
The obtained sample was examined by infrared 
absorption spectral analysis and was compared with the 
reference standard IR spectrum of API. Also UV 
spectrum was taken to identify the compound based on 
λmax and peak shape. 
Organoleptic characteristics: 
The color, odour and taste of the drug were 
characterized and recorded using descriptive 
terminology. 
Solubility of drug:  
The solubility of Drug  was determined as per BCS. The 
solubility was checked in 250 ml of 0.01N HCl with 
0.5% SLS and buffers within pH range 2 – 8. The 
highest amount of dose was accurately weighed and 
transferred in individual volumetric flask containing 
different solutions and sonicate for 30 minutes. 
Interpretation was done based on BCS classification 
which states that drug is BCS class II. 
Pre compression parameters : 
a) Angle of repose : Angle of repose of the granules 
will be measured by the fixed height method.  
 = tan-1 h/r   = Angle of repose 
                                    h   = Height of powder heap 
                                    r   = Radius of the powder cone 
b) Bulk density : The powder sample equivalent to 
10g will be accurately weighed,  will fill in a 50 ml 
graduated cylinder, the powder will be levelled & 
the unsettled volume (Vi) will be noted. The bulk 
density will be calculated in g/cm3 by the formula. 
ρi   = m /Vi m   = mass of the blend 
Vi    = untapped volume 
c) Tapped density :  
ρt = m/Vt  Vt is tapped volume 
d) Hausner’s Ratio : It is measurement of frictional 
resistance of the drug .The ideal range should be 
1.2-1.5. It will be determined by the ratio of tapped 
density and bulk density. 
Tapped density/bulk density 
e) Carr’s index : Based on the bulk density & tapped 
density, the percentage compressibility of the 
granules will be computed using the Carr’s 
compressibility index by the formula, 
(Tapped density-bulk density)*100/Tapped density 
Post compression parameters: 
a) Weight Variation : Will be done as per USP 
b) Thickness :  Will be Measured by Vernier Calipers 
c) Hardness :  Will be Measured by Monsanto 
Hardness Tester 
d) Friability : Will be Measured by Roche friabilator 
                  %Friability = (W1-W2/W2)*100 
                  W1= weight of tablets before test 
                  W2= weight of tablets after test 
e) In-Vitro dissolution study: 
An in-vitro dissolution study  will be carried out in 
• Dissolution medium:  0.5% sodium lauryl sulphate 
(SLS) in   900 ml of Phosphate buffer (pH 6.8) with 
type II paddle.  
• Temperature: 37±0.5.C 
• Stirring speed of Paddle:50rpm 
• Time Point(hr): 1,2,3,4,5,6,7,8,9,10,11,12 
• Sample amount: 5ml 
• Volume: 900ml 
Method of preparation: 
Melt granulation method: The waxes(Compritol 888 
ATO& Precirol ATO 5) was melted in a porcelain dish 
over a water bath maintained at 75-80°C for 3 min and 
Nateglinide was gradually added with continuous 
stirring until uniformly mixed. The molten mixture was 
allowed to cool and solidify at room temperature 
crushed in a mortar and passed through a 40# sieve. The 
granules were compressed into flat–faced tablet using 
multi-station rotary tablet compression machine 
(Krishna engineering Pvt. Ltd. India) at a constant 
compression force. 
Evaluation of drug - Excipient interaction: The pure 
drug, wax and the matrix tablet formulation were 
subjected to IR spectroscopy using FT-IR 
spectrophotometer. Their spectra were obtained over the 
wave number range of 4000 – 400 cm-1. 
In-vitro drug release: In vitro release studies were 
conducted using USP type II paddle apparatus (VDA-
6D USP Std -VEEGO) run at 50 rpm. The buffer was 
kept at thermostatically controlled temperature of 
37±0.5°C. The test was carried out in 900 ml of 0.01 M 
HCl for 2 h and then replaced with phosphate buffer 
(pH 6.8) as the dissolution medium for another 10 h. 
The pH change of medium was effected by adding 
4.32g of sodium hydroxide and 6.08 g of potassium 
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dihydrogen phosphate dissolved in 5 ml water to the 
previous acidic medium (0.1 M HCl)(17). Five 
milliliters samples were withdrawn at the time intervals 
of 1, 2, 3, 4, 5, 6….12 and replaced with equal volume 
of fresh dissolution medium. The samples were filtered 
through 0.45 µm filter and analyzed for drug content at 
218 nm by UV spectrophotometer. 
 
Formulation: 
Table 1:  Identical formulation table for all batches 
Polymer used Precirol ATO 5 Compretol 888 
 25% 35% 45% 25% 35% 45% 
Drug (NATEGLINIDE) 324 324 324 324 324 324 
Polymer 162.5 227.5 292.5 162.5 227.5 292.5 
Dicalcium phoshphate 144 79 14 144 79 14 
Mg.Stearate 13 13 13 13 13 13 
Aerosil 200 6.5 6.5 6.5 6.5 6.5 6.5 
TOTAL 650mg 650mg 650mg 650mg 650mg 650mg 
 
RESULTS 
Interaction between drug and wax was checked by FT-IR Spectroscopy. 
 
Figure 2: IR Spectrum of all excipients & Nateglinide 
1. DIRECT COMPRESSION 
Table 2: Pre-compression parameters of batch F1-F6 (Direct compression) 
Formulatio
n 
Angle of 
Repose(°) 
(n=3) ±SD 
Loose Bulk 
Density 
(g/cm3) ±SD 
Tapped Bulk 
Density 
(g/cm3) ±SD 
Hausners 
Ratio±SD 
Carr’s Index 
(%)±SD 
F1 30.81±0.90 0.43±0.030 0.53±0.036 1.23±0.052 18.86±0.77 
F2 29.75±0.81 0.44±0.034 0.56±0.028 1.27±0.060 21.40±0.25 
F3 29.19±0.68 0.46±0.028 0.57±0.052 1.24±0.031 19.29±0.16 
F4 28.40±0.74 0.47±0.019 0.58±0.043 1.23±0.047 18.98±0.29 
F5 30.18±0.65 0.45±0.043 0.56±0.042 1.24±0.063 19.64±0.45 
F6 32.39±1.02 0.46±0.035 0.57±0.051 1.23±0.058 19.29±0.87 
 
Table 3: Post-compression parameters of batch F1-F6 (Direct compression) 
Formulation Hardness 
(Kg/Cm
2
) ±SD 
Friability 
(%) 
Weight variation(mg) 
±SD 
Drug Content(%) 
±SD 
Swelling 
index (%) 
F1 6.3±0.60 0.23 649±5.12 98.51±0.60 10.1 
F2 6.5±0.28 0.21 650±4.94 99.12±0.42 25.6 
F3 6.4±0.40 0.19 648±6.39 99.82±0.48 37.9 
F4 6.5±0.71 0.17 650±5.38 99.54±0.71 24.4 
F5 6.4±0.80 0.14 649±4.29 99.89±0.38 41.9 
F6 6.4±0.58 0.13 649±4.35 99.64±0.66 54.6 
 
Patel et al                                          Journal of Drug Delivery & Therapeutics. 2015; 5(5):19-25 22 
© 2011-15, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
Table 4: In-Vitro Drug Release data of F1 to F6 
Time (h) In-Vitro Drug Release at 37
0
±0.5°C, 50 RPM 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
1 3.11 2.63 2.34 2.5 3.13 0.85 
2 10.26 11.13 5.6 8.38 6.43 1.18 
3 17.22 14.82 9.32 12.27 8.57 2.1 
4 26.62 17.21 13.53 18.53 12.38 4.17 
5 30.39 18.33 17.11 22.64 14.75 6.42 
6 33.67 21.46 21.34 29.52 19.37 9.1 
7 34.28 24.52 24.66 33.77 23.56 11.4 
8 39.88 26.67 27.43 36.5 27.54 13.34 
9 42.31 29.33 29.16 39.71 30.64 15.72 
10 47.37 31.74 31.42 42.35 34.77 17.36 
11 51.32 41.03 33.48 43.66 41.36 19.83 
12 53.63 46.12 37.78 44.15 45.87 21.43 
 
  
Figure 3: In-VitroIn-Vitro Drug Release of formulations F1 to F6 
2. CO-PROCESSING 
Table 5: Pre-compression parameters of batch F7-F12 (Co-processing) 
Formulatio
n 
Angle of 
Repose(°) 
(n=3) ± S.D 
Loose Bulk 
Density 
(g/cm3) ±S.D 
Tapped Bulk 
Density 
(g/cm3)  ±S.D 
Hausners Ratio) 
±S.D 
Carr’s Index 
(%)) ±S.D 
F7 31.22±0.84 0.45±0.021 0.56±0.054 1.24±0.061 19.64±0.93 
F8 33.04±0.32 0.46±0.037 0.55±0.044 1.19±0.052 16.35±0.61 
F9 29.65±0.55 0.44±0.024 0.54±0.041 1.22±0.047 22.72±0.45 
F10 27.25±0.74 0.47±0.029 0.56±0.063 1.20±0.084 16.18±0.77 
F11 28.58±0.86 0.45±0.027 0.54±0.032 1.20±0.063 16.66±0.45 
F12 31.20±0.40 0.46±0.035 0.57±0.061 1.23±0.038 19.29±0.57 
 
Table 6: Post-compression parameters of batch F7-F12 
Formulation Hardness 
(Kg/Cm
2
) ±SD 
Friability (%) Weight variation(mg) ±SD Drug 
Content(%)±SD 
Swelling 
index (%) 
 
F7 6.7±0.27 0.14 650±4.08 99.85±0.12 12.3 
F8 6.2±0.84 0.12 648±3.97 99.56±0.34 23.5 
F9 6.4±0.79 0.10 649±6.41 98.17±0.87 39.6 
F10 6.3±0.61 0.15 648±5.92 97.9±0.65 23.7 
F11 6.6±0.85 0.15 649±7.81 99.74±0.14 43.6 
F12 6.7±0.93 0.13 650±4.16 98.89±0.10 61.8 
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Table 7: In-Vitro Drug Release datas of F7 to F12 
 
Time (h) 
In-Vitro Drug Release at 37
0
±0.5°C, 50 RPM 
F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
1 10.10 4.55 3.67 11.60 15.86 1.94 
2 18.47 11.43 11.12 23.72 27.06 3.83 
3 28.33 19.24 16.55 33.47 34.12 5.96 
4 37.44 25.35 22.80 37.56 41.37 8.1 
5 43.60 36.76 27.49 42.33 44.16 9.73 
6 48.72 41.40 31.36 49.13 48.43 13.43 
7 54.43 48.69 35.21 57.15 51.20 16.6 
8 63.34 53.23 41.17 61.48 55.63 19.58 
9 71.56 59.92 44.83 65.52 59.55 22.67 
10 77.89 63.53 49.59 68.84 62.74 24.14 
11 85.54 70.47 52.58 72.48 65.38 28.45 
12 87.92 75.01 56.71 83.20 66.47 33.32 
 
   
Fig 4: In-VitroIn-Vitro Drug Release of formulations F7 to F12 
3. MELT GRANULATION 
Table 8: Pre-compression parameters of batch F13-F18 
 
Formulation 
Angle of Repose(°) 
(n=3) 
Loose Bulk Density 
(g/cm3) 
Tapped Bulk Density 
(g/cm3) 
Hausners 
Ratio 
Carr’s Index 
(%) 
F13 18.20±0.88 0.59±0.030 0.66±0.045 1.12± 0.06 10.06±0.72 
F14 19.87±0.43 0.67±0.028 0.72±0.032 1.07± 0.05 6.94±0.93 
F15 17.07±1.01 0.58±0.034 0.64±0.037 1.10±0.07 9.37±0.60 
F16 19.41±0.98 0.62±0.042 0.68±0.029 1.09±0.07 8.88±0.43 
F17 19.43±0.79 0.57±0.011 0.62±0.050 1.08±0.09 8.09±0.38 
F18 16.65±0.47 0.57±0.052 0.63±0.064 1.19±0.04 9.52±0.62 
 
Table 9: Post-compression parameters of batch F13-F18 
Formulation Hardness 
(Kg/Cm
2
) ±SD 
Friability (%) Weight variation(mg) ±SD Drug Content(%) 
±SD 
Swelling 
index (%) 
 
F13 6.5±0.38 0.13 650±4.65 99.89±0.50 22.9 
F14 6.8±0.61 0.14 647±5.29 99.89±0.76 36.4 
F15 6.3±0.29 0.13 648±3.39 99.89±0.47 42.3 
F16 6.4±0.51 0.19 649±5.02 99.89±0.58 29.1 
F17 6.6±0.27 0.14 648±4.92 99.64±0.60 34.9 
F18 6.2±0.74 0.17 500±5.16 99.85±0.34 53.5 
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Table 10: In-Vitro Drug Release datas of F13 to F18 
 
Time (h) 
In-Vitro Drug Release at 37
0
±0.5°C, 50 RPM 
F13 F14 F15 F16 F17 F18 
0 0 0 0 0 0 0 
1 11.47 11.06 8.43 9.12 10.21 7.42 
2 24.42 19.65 14.96 11.36 16.80 11.15 
3 40.62 33.04 23.25 20.82 24.15 17.14 
4 48.99 38.47 28.74 36.74 28.68 20.96 
5 58.79 46.07 33.62 43.06 34.49 25.41 
6 67.13 53.34 38.39 50.61 41.06 28.94 
7 72.47 60.62 43.53 62.21 47.44 32.12 
8 79.05 66.07 48.68 76.15 51.88 36.06 
9 84.05 70.84 52.42 83.90 59.34 39.15 
10 90.36 75.05 56.43 89.97 64.89 42.88 
11 92.13 82.61 62.12 91.25 66.21 48.25 
12 94.55 86.54 68.32 92.10 71.45 54.13 
 
 
 
Fig 5: In-VitroIn-Vitro Drug Release of formulations F13 to F18 
 
DISCUSSION: 
The study showed that Precirol ATO 5 is an appropriate 
waxy matrix former for sustained release of low water-
soluble drug such as Nateglinide.MG technique fits 
completely into the predetermined parameter and 
criteria whereas, other two techniques lack behind. 
Sustained release profiles can be achieved by any of 
three methods using Precirol ATO 5 at higher 
proportion but MG technique achieved 12 h release 
profile with lesser amount of was as compare to other 
methods. Formulation F13 was given 94.55% drug 
release in 12h which was optimizing batch. 
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